ArticleFrontiers in oncology2022

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201).

Yuqin Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.